An observational study in Diabetes Mellitus, sponsored by University of Bern. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-08.
Sponsored by University of Bern · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 87 studies in Diabetes Mellitus with a site in Switzerland — 9 open to participants now, 11 under way, none of them phase 3. Diabetes Mellitus · Switzerland.
Among the 87 studies in Diabetes Mellitus with a site in Switzerland, this one is the 18th largest by planned enrollment of the 24 observational ones that give a count, is one of 7 that started in 2023, is one of 24 observational ones, reaches primary completion later than 2 of the 10 other live ones, and was the 80th registered.
8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.
Browse Diabetes Mellitus studies →9 of the 87 studies in Diabetes Mellitus with a site in Switzerland are open now. Recruiting first, the newest first:
University Hospital, Geneva · Sites in Switzerland
Ages 18+
Medtronic Vascular · Sites in Switzerland, United States, Australia and 3 more countries
Ages 18–80
Sleepiz AG · Sites in Switzerland
Ages 18+ · Healthy volunteers
University Hospital, Basel, Switzerland · Sites in Switzerland, Lesotho
Healthy volunteers
University of Lausanne · Sites in Switzerland
Ages 60–80 · Healthy volunteers
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
87 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 10 · Phase 3 19 · Phase 4 4
First in 1994; this study’s year is marked. 7 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 246 across 1,935 observational studies indexed under Diabetes Mellitus.
Median enrollment 141 across the 63 interventional studies, 600 across the 24 observational. Of the 67 that completed or were terminated, 11 (16%) have results posted.
This tab as a report to print or save as PDF → With an account.
40 of 87 have an industry lead sponsor. The 10 most frequent:
University of Bern is the lead sponsor of 209 studies on the registry; 46 are open to participants now.
University of Bern has 3 studies filed under Diabetes Mellitus — fewer than ten, so there is no comparison to draw.
3 of the studies in Diabetes Mellitus with a site in Switzerland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06715514Lia BallyMenopausal Hormone Therapy, GLP-1 Agonists, and Glucose and Energy Homeostasis in Postmenopausal Women With Overweight/Obesity and Impaired Glucose Homeostasis | 2026-12-17 |
| NCT07506356University Hospital, GenevaInvestigation of Gastric Emptying by Gastric Ultrasonography in Diabetic Patients Treated With GLP-1 Receptors | 2026-12-31 |
| NCT07036471University of Geneva, SwitzerlandSupporting Patients Starting New Medicines: Evaluating the myCare Start Service in Switzerland | 2027-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 87 studies in Diabetes Mellitus with a site in Switzerland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Exhaled volatile organic compounds will be measured during daytime with the goal to identifying circadian variability. The study incudes three subgroups: people without diabetes, people with type 1 diabetes, and people with type 2 diabetes. A total of 60 people will be recruited for the study.
60 participants with the following subgroups: Subgroup 1: People without diabetes Subgroup 2: People diagnosed with T1D Subgroup 3: People diagnosed with T2D
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subgroup 1:
Subgroup 2:
Subgroup 3
Exclusion criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: Standardized meal
Other: Standardized meal
Other: Standardized meal
The participants will receive a standardized meal for breakfast
VOC Patterns over time as gallery plots
Gallery plots (3D visualization of retention index, drift time, ion current) from selected VOC peaks over time.
Time frame: During the study procedure (approximately 8 hours)
VOC Patterns over time as boxplots
Box plots from selected VOC peaks over time.
Time frame: During the study procedure (approximately 8 hours)
Capillary blood glucose
Correlation between capillary blood glucose and VOCs
Time frame: During the study procedure (approximately 8 hours)
Correlation between VOCs in breath intestinal microbiota
Correlation between VOCs in breath and intestinal microbiota species abundance
Time frame: day 1
Correlation between VOCs in breath oral microbiota
Correlation between VOCs in breath and oral microbiota species abundance
Time frame: day 1
Correlation between VOCs and subgroups
Wilcoxon signed-rank test will be used to explore if the patterns in VOCs differ between subgroup: people without diabetes, people living with T1D, and people living with T2D
Time frame: day 1 or 8 hours
Plan to share: No
Started Aug 2023 (actual). Primary completion is estimated for Jun 2026, 34 months after the start.
Of 534 non-industry observational studies under Diabetes Mellitus, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 159. This study's planned 34 months is below that.
Counting every sponsor, half of 643 studies reached it within 36 months; a quarter within 14 and three quarters within 122.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.